In this webinar, we’ll examine the challenges that have historically limited progress in neurotherapeutics and introduce a suite of advanced neuro platforms built to overcome them.
‍

What You’ll Learn
‍

• An overview of three complementary neuro platforms, each with distinct hallmarks and applications for safety and efficacy testing.
• A deep dive into a functional brain organoid model featuring consistent spontaneous network activity, enabling robust predictive capabilities.
• Insights into the development of a predictive neurotoxicity assay designed to reduce clinical failures due to CNS toxicity and seizure liability.
• A case study in Rett Syndrome drug discovery, demonstrating how a human 3D organoid model delivers critical insights into drug safety and efficacy.

‍

Speaker
‍

Andrew LaCroix, PhD
‍

Andrew LaCroix is a Lead Scientist at 28 bio specializing in the development of iPSC-derived brain organoid models and their applications to preclinical safety and efficacy testing. Specifically, he has focused on predictive neurotoxicity assays and human-first drug discovery to reduce clinical failure rates and improve patient outcomes.